6.03
0.99%
-0.06
Recursion Pharmaceuticals Inc stock is traded at $6.03, with a volume of 19.49M.
It is down -0.99% in the last 24 hours and down -0.17% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.09
Open:
$6
24h Volume:
19.49M
Relative Volume:
2.17
Market Cap:
$2.36B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-4.3696
EPS:
-1.38
Net Cash Flow:
$-335.64M
1W Performance:
-13.24%
1M Performance:
-0.17%
6M Performance:
-34.10%
1Y Performance:
-36.26%
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.03 | 2.36B | 64.60M | -377.75M | -335.64M | -1.55 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
Mar-16-23 | Initiated | Needham | Buy |
Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Sep-21-21 | Initiated | Berenberg | Buy |
May-11-21 | Initiated | BofA Securities | Buy |
May-11-21 | Initiated | Goldman | Neutral |
May-11-21 | Initiated | JP Morgan | Neutral |
May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - The Manila Times
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7%Here's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% HigherHere's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals registers shares for Tempus Labs - Investing.com India
Recursion Pharmaceuticals registers shares for Tempus Labs By Investing.com - Investing.com UK
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5%Here's What Happened - MarketBeat
State Street Corp Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX) - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3%What's Next? - MarketBeat
Interesting RXRX Put And Call Options For January 2025 - Nasdaq
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials - Insider Monkey
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7%Here's Why - MarketBeat
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Receives Buy Rating from Needham & Company LLC - MarketBeat
10 AI News Investors Probably Missed - Insider Monkey
(RXRX) Trading Report - Stock Traders Daily
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Recursion Pharmaceuticals - Benzinga
What's Going On With Recursion Pharmaceuticals Stock?Recursion Pharmaceuticals (NASDAQ:RXRX) - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.5% HigherShould You Buy? - MarketBeat
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 (NASDAQ:RXRX) - Seeking Alpha
Charles Schwab Investment Management Inc. Has $12.79 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Fmr LLC Buys 170,810 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Benjamin Edwards Inc. - MarketBeat
Recursion Pharmaceuticals CEO sells $285,600 in stock By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells $285,600 in stock - Investing.com India
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.7%Time to Buy? - MarketBeat
Stock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9%Should You Sell? - MarketBeat
The Future of Medicine: How AI Is Transforming Healthcare and Stock Markets - Baystreet.ca
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):